32 results about "Ribavirin" patented technology

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The utility model discloses a ribavirin injection batching device which comprises a main body tank, a cover plate is arranged at the upper end of the main body tank, a rubber sealing gasket is connected to the lower end of the cover plate through a pipeline, the rubber sealing gasket is arranged in the main body tank, a feeding port is formed in the cover plate and the rubber sealing gasket in a penetrating mode, and the feeding port is communicated with the interior of the main body tank. A flow guide assembly is arranged in the main body tank, a transmission bin is formed in the main body tank, a transmission assembly is arranged in the transmission bin and used in cooperation with the flow guide assembly, and a discharging port and an observation window are fixedly connected to the surface of the main body tank. By means of the design, a complete vertical stirring channel is formed, the solution is effectively mixed, it is ensured that the formula is uniform, and at the moment, the second flow guide fan synchronously runs to assist the solution above to be distributed to the bottom to be redistributed.

The invention discloses an aryl oxadiazole compound with a chemical structural formula as shown in the specification or pharmaceutically acceptable salt thereof. In-vitro experiment results show that the compound has a remarkable inhibition effect on DENV, the therapeutic index (TI) of the compound is far higher than that of a clinical reference substance ribavirin, the TI value of a preferred compound such as I-29 exceeds 1131.86, and the TI value of the preferred compound is far higher than that of the clinical reference substance ribavirin. The characteristics of high efficiency and low toxicity are highlighted. In addition, the preparation method is simple in process, high in yield, mild in reaction condition and suitable for large-scale production and clinical popularization.

The present disclosure relates to a ribavirin derivative-embedded double-stranded siRNA analogue, a conjugate comprising the same, and salts and uses thereof. The double-stranded siRNA analogue, the conjugate comprising the same, and the salts thereof of the present disclosure can effectively inhibit multiple viral indicators such as hepatitis B virus DNA, pgRNA, S antigen, E antigen, etc., and provide an effective and feasible method for the treatment of hepatitis B.

The present application relates to the technical field of water treatment, and particularly relates to a method for degrading a triazole nucleoside antiviral drug in water. The method comprises the following steps: adding a chloramine disinfectant to a water sample to be treated, and then placing the water sample in an ultraviolet light irradiation environment to perform a photo-induced oxidation reaction, wherein the wavelength of the ultraviolet light is 200-300 nm, the irradiation intensity is 0.079-0.25 mW / cm 2 , the temperature is 10-30 DEG C, and the time is 90-150 min, so as to destroy the chemical structure of the drug and degrade the triazole nucleoside antiviral drug. The method utilizes the synergy of ultraviolet and chloramine combined disinfection to economically and efficiently remove the triazole nucleoside antiviral drug in water, without the need to add additional equipment and reagents, and the operation is simple.

This invention discloses a method for virus-free tissue culture using terminal buds of *Prunus armeniaca* rootstock, belonging to the field of plant tissue culture technology. The method includes: selecting terminal buds of *Prunus armeniaca* rootstock for pretreatment, sterilizing them with ethanol and mercuric chloride, and then immersing them in a virus-free pretreatment solution containing ribavirin and triazole nucleoside for virus removal; inoculating the virus-free terminal buds into WPM-based differentiation induction medium to obtain clustered buds; culturing the clustered buds in 1 / 2 MS-based proliferation subculture medium to obtain proliferating buds; inoculating the proliferating buds into 1 / 3 MS-based rooting medium to induce rooting; and finally, after hardening off and transplanting into a vermiculite-garden soil-humus substrate for acclimatization. This invention optimizes the virus removal and tissue culture system based on the characteristics of *Prunus armeniaca* rootstock, achieving a virus removal rate ≥95%, a terminal bud differentiation survival rate ≥85%, a rooting rate ≥90%, and a transplant survival rate ≥88%. This enables rapid and large-scale propagation of virus-free *Prunus armeniaca* rootstock seedlings, solving the problem of low propagation efficiency in traditional methods and providing high-quality rootstock support for the *Prunus armeniaca* industry.

The present application provides combinations of bulevirtide, or a pharmaceutically acceptable salt thereof, and ribavirin, or a pharmaceutically acceptable salt thereof, useful for treating hepatitis D virus (HDV) infection.

A method of treating a COVID-19 infection includes administering to a subject in need thereof an effective amount of a composition, where the composition includes silica nanoparticles, superparamagnetic iron oxide nanoparticles (SPIONs), chitosan, cisplatin, ribavirin, and an angiotensin-converting enzyme 2 (ACE-2). The SPIONs and ACE-2 are dispersed on an outer surface of the silica nanoparticles. The chitosan at least partially wraps around the outer surface of the silica nanoparticles. The cisplatin and ribavirin are in pores of the silica nanoparticles. The composition is in the form of particles that are monodisperse, are spherical, and have an average diameter of 70-100 nanometers (nm).

The invention discloses a traditional Chinese medicine composition for preventing and treating chikungunya fever as well as a preparation method and application of the traditional Chinese medicine composition. The composition is prepared from sweet wormwood herb, honeysuckle flower, giant knotweed rhizome, coix seed, red paeony root and liquorice root according to a specific ratio, and has the effects of clearing away heat and toxic materials, eliminating dampness and promoting superficies, and promoting blood circulation to remove meridian obstruction on the basis of the theory of'warm pathology '. Experiments show that the composition can significantly inhibit chikungunya virus replication (EC = 47.2 [mu] g / mL), has better effects than ribavirin and isatis root, and can effectively relieve fever and arthralgia. The invention also provides a plurality of dosage forms such as decoction, granules and spray, is suitable for large-scale prevention and clinical treatment of epidemic areas, and has the advantages of multi-link effectiveness, low cost and small side effect.

The invention discloses an aryl bishydrazide compound with a structural formula shown in the following formula: in-vitro experiment results show that the compound has remarkable inhibitory activity on dengue virus (DENV), the therapeutic index (TI) of the compound is remarkably higher than that of a clinical positive control drug ribavirin, and in addition, the compound can be used for preparing an aryl bishydrazide compound with the structural formula shown in the specification. The preparation method disclosed by the invention is simple and efficient in process, good in yield and mild in reaction condition, has good large-scale production potential, and provides a feasible synthesis basis for further clinical transformation and application.

The invention belongs to the technical field of medical chemistry, and particularly relates to a fungal anti-enterovirus sesquiterpene compound as well as preparation and application thereof. A compound with anti-EV71 activity is screened from natural products, the sesquiterpenoids are extracted from a fermentation culture of plant endophytic fungi Paramrothecium sp. Q021, the sesquiterpenoids have remarkable anti-EV71 virus activity, the half effective concentration (EC50) of the sesquiterpenoids is remarkably lower than that of ribavirin, and the sesquiterpenoids have the advantages that the sesquiterpenoids have obvious anti-EV71 virus activity; meanwhile, the half cytotoxicity concentration (CC50) and the selection index (SI index) of the ribavirin are higher than those of the ribavirin. The results show that the sesquiterpenoids have remarkable anti-EV71 virus activity and excellent safety, a candidate compound with great potential is provided for developing a novel medicine for preventing and treating the infant hand-foot-and-mouth disease caused by the EV71 virus, and the sesquiterpenoids have a good application prospect.

The invention provides a diaminopyrimidine compound with a structure as shown in a formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, and an application of the diaminopyrimidine compound, or the stereoisomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof, or the prodrug molecule thereof, or the deuteride thereof, or the tritium thereof. The diaminopyrimidine compound provided by the invention has obvious inhibitory activity on RSV virus, has a chemical structure type completely different from that of the existing anti-RSV drug ribavirin and the like, is expected to be developed into a novel anti-RSV drug, is used for inhibiting replication or reproduction of the RSV virus, and has broad application prospects. The pharmaceutical composition can be used for preventing, relieving and / or treating respiratory syncytial virus infection and cytopathic effects caused by the respiratory syncytial virus infection, and can be used for treating bronchitis or pneumonia and other diseases caused by the respiratory syncytial virus infection.

The present application provides a virus detoxification method of Chinese yam. The present application can effectively prevent Japanese yam mosaic virus (JYMV), potato virus Y (PVY), potato virus X (PVX) and potato leaf roll virus (PLRV) by peeling the stem tip of Chinese yam and using heat treatment and ribavirin detoxification. The optimal virus removal method is to peel the stem tip to 0.3-0.5mm, heat treatment at 40℃ for 8h, and ribavirin 50mg / L.

The application discloses a Marburg virus-based micro-genome replication-defective system and application thereof, and belongs to the field of biological medicine. The system significantly improves the expression efficiency and signal-to-noise ratio of a model reporter gene through a codon optimization strategy. Experimental verification shows that the model can safely simulate the MARV genome replication and transcription process under a biosafety level 2 (BSL-2) condition, and has high specificity and sensitivity. Through parallel verification of positive drugs such as ribavirin, suramin sodium salt and negative controls such as oseltamivir, it is confirmed that the model can accurately and quantitatively evaluate the activity of small-molecule drugs targeting the replication link of the virus and calculate EC50. The model provides a safe and efficient platform for the study of the MARV replication mechanism and the high-throughput screening of antiviral drugs, breaks through the limitation of a biosafety level 4 laboratory, and has important scientific research and application value.

The application relates to a limonoid compound Aglatestate F, a preparation method and application thereof, and belongs to the field of chemical medicines. The compound is obtained by separation and extraction from branches and leaves of Aglaia edulis, and preparation and separation are simple. The compound has a good inhibiting effect on dengue virus BHK-21 cell infection, and the compound has a good inhibiting effect on dengue virus BHK-21 cell infection at a non-toxic concentration, the anti-dengue virus effect EC 50 = 1.290+ / -0.170, and the selectivity index is higher than that of the positive drug antiviral drug ribavirin, so that the compound Aglatestate F has a good development prospect of anti-dengue virus drugs, and lays a solid foundation for preparation of anti-dengue virus drug development.

To address the low removal efficiency of ribavirin and chloroquine phosphate, two common antiviral drugs, in traditional wastewater treatment methods, this invention provides a method for treating ribavirin and chloroquine phosphate in water using ultraviolet photocatalysis. This invention removes ribavirin and chloroquine phosphate by adding a certain amount of TiO2 and KMnO4 to the water under ultraviolet irradiation. Results show that the UV / KMnO4 / TiO2 process can efficiently remove ribavirin and chloroquine phosphate, with a treatment effect far exceeding that of UV alone, UV / KMnO4, or UV / TiO2 methods, indicating a significant synergistic effect. Furthermore, since TiO2 is currently the most common photocatalytic material, and potassium permanganate (KMnO4) is a common oxidant, the UV / KMnO4 / TiO2 method is simple, readily available, and easy to implement, making it widely applicable in engineering practice.

Provided are a ribavirin derivative-embedded double-stranded siRNA analog, a conjugate comprising the same, and a salt and use thereof. The provided double-stranded siRNA analog, the conjugate comprising the same, and the salt thereof can effectively inhibit multiple viral indicators such as hepatitis B virus DNA, pgRNA, S antigen, E antigen, etc., and provide an effective and feasible method for the treatment of hepatitis B.

This invention relates to a cyclopentanephenylpropionate furan compound, Aglatestate E, its preparation method, and its applications, belonging to the field of pharmaceutical chemistry. Aglatestate E was first extracted and isolated from *Aglaia edulis*, and its structural formula is (I). The cyclopentanephenylpropionate furan compound Aglatestate E of this invention exhibits excellent anti-dengue virus and anti-tumor activity against dengue virus 2-infected BHK-21 cells and tumor cells. Its anti-dengue virus activity is stronger than that of the positive control drug ribavirin, and its inhibitory activity against human colon cancer cells HCT-116 is stronger than that of the positive control drug doxorubicin. It can be used to prepare anti-dengue virus and anti-tumor drugs. This invention also relates to a pharmaceutical composition comprising the above-mentioned Aglatestate E and pharmaceutically acceptable excipients, which has anti-dengue virus and anti-tumor effects.

This invention provides a pharmaceutical composition and its application. The pharmaceutical composition of this invention comprises ribavirin and mycophenolate mofetil or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of this invention can be used to prepare an antiviral drug, and the two active components exhibit a synergistic antiviral effect against influenza.

The present application provides the use of MIR2911 in the preparation of drugs against yellow fever virus YFV. Compared with the prior art, the present application has the following advantages: the application provided by the present application innovatively proposes a strategy for inhibiting YFV replication using MIR2911 small nucleic acid drugs, which can specifically target multiple genes of YFV and more effectively inhibit YFV replication than ribavirin; cell experiments have verified the inhibitory effects at the mRNA, protein and virus particle levels. The RNA sequence that ultimately exerts the effect is encapsulated and transported by endogenous exosomes, and there is no immune response. There is no need to verify the safety of exosomes, and it can also compensate for individual differences in oral MIR2911. Compared with protein and peptide drugs with a single target on the market, it is low-cost and more efficient.

The invention relates to the field of pharmaceutical preparations, and particularly discloses a ribavirin spray and a preparation method thereof. The method comprises the following core steps: pre-treating raw materials and auxiliary materials in a D-grade clean area; a step-by-step process of firstly dissolving auxiliary materials and then adding raw materials is adopted in the C-grade clean area to prepare liquid medicine; enabling the liquid medicine to pass through a three-stage filtration system comprising rough filtration, fine filtration and terminal sterilization filtration, and hermetically transferring the liquid medicine to a B-stage clean area under positive pressure; and finally, carrying out sterile filling and sealing in an A-grade laminar flow protection environment under a B-grade background, and carrying out sealing integrity and spraying performance detection on a finished product. According to the invention, the ribavirin spray which is uniform in spray particle size, accurate in administration dosage and high in sterility assurance level can be stably produced by constructing a graded clean production process, accurately controlling key process parameters and implementing quality monitoring in the whole process, and meanwhile, high efficiency and energy conservation of the production process are realized.

Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and / or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and / or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and / or combinations thereof as an inhaled dry powder treatment for COVID-19 and / or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and / or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and / or sonodynamic therapy (PDT / SDT).

The application provides application of MIR2911 in preparation of a drug for resisting dengue virus DENV. Compared with the prior art, the application has the following advantages: the application provided by the application innovatively proposes a strategy of inhibiting DENV replication by using MIR2911 small nucleic acid drugs, can specifically target multiple genes of DENV, and can more effectively inhibit the replication of DENV compared with ribavirin; cell experiments verify the inhibitory effect at the mRNA, protein and virus particle levels. The RNA sequence finally plays an effect is delivered by endogenous exosomes, does not exist any immune response, does not need to verify the safety of exosomes, and can also compensate for individual differences of oral MIR2911. Compared with protein polypeptide drugs with a single target on the market, the cost is low and more efficient.

The invention discloses a compound traditional Chinese medicine aqueous extract for preventing and treating infectious bronchitis as well as a preparation method and application thereof, and belongs to the field of veterinary traditional Chinese medicine preparations. The aqueous extract is prepared from rhizoma pinellinae praeparata, bulbus fritillariae thunbergii, pericarpium citri reticulatae, liquorice, platycodon grandiflorum and semen armeniacae amarae according to a specific proportion through water extraction and concentration. Aiming at the defects of an existing prevention and treatment scheme in recovery of the growth performance and immune function of the infected chicken, the invention innovatively adopts a treatment rule formula of combining qi regulating, spleen strengthening, dampness eliminating, phlegm reducing and lung qi diffusing and lowering. Animal experiments show that the compound can effectively inhibit avian infectious bronchitis virus replication, can significantly improve the thymus index of infected chicks, and enables the average daily gain of the chicks to recover to a level that the average daily gain is not significantly different from that of a healthy group, and the synergistic effect is significantly higher than that of a ribavirin positive control group. The composition is simple in component, stable in process and good in safety, and a new product is provided for green and efficient prevention and treatment of infectious bronchitis.

The present application relates to the technical field of biological medicine, in particular to the application of ribavirin or unsaturated hyaluronic acid disaccharide in the preparation of drugs for preventing and treating Alzheimer's disease. The present application discloses for the first time that ribavirin and unsaturated hyaluronic acid disaccharide can significantly inhibit the aggregation of beta-amyloid protein in vitro. The cell toxicity induced by the aggregation of beta-amyloid protein can be significantly reduced. Ribavirin can reduce the aggregation of A beta42 on the body wall of AD model nematode CL4176. It is proved that ribavirin has the effect of resisting Alzheimer's disease. In vivo, unsaturated hyaluronic acid disaccharide can improve the movement ability of AD model nematode CL4176, and prolong the life span of CL4176. It is proved that unsaturated hyaluronic acid disaccharide and ribavirin have the effect of resisting Alzheimer's disease, and can be applied to the preparation of drugs for preventing and treating Alzheimer's disease.

The present application provides combinations of ribavirin, or a pharmaceutically acceptable salt thereof, and an additional therapeutic agent, useful for treating hepatitis D virus (HDV) infection.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to application of an alkaloid compound in preparation of a product with a respiratory syncytial virus resisting effect. The alkaloid compound with a brand new chemical structure is extracted from peganum harmala, the compound shows very remarkable respiratory syncytial virus resistance activity, and the activity intensity of the compound is equivalent to that of a positive drug ribavirin. Meanwhile, the selection index (SI value) of the compound is greater than 13.8, which indicates that the safety range of the compound is larger, and the use safety can be better guaranteed while the drug effect is exerted. Therefore, the compound serving as an active ingredient is used for preparing medicines or health-care products with the effect of resisting the respiratory syncytial virus, and has important application value and wide development prospect.

The application discloses a ribavirin and PD-1 inhibitor combined drug composition and application thereof. Based on cell experiments and animal model research, it is proved that the ribavirin and PD-1 inhibitor combined use has a remarkable treatment effect on lung cancer. The ribavirin and PD-1 inhibitor combined drug composition provided by the application overcomes the problem of unsatisfactory single treatment effect of tumor diseases, and the combined treatment remarkably enhances the anti-tumor treatment effect, especially the treatment effect on lung cancer.

The application provides a 3'-O-beta-glucosyl-ribavirin compound and a preparation method and application thereof, and the method comprises the following steps: taking uridine diphosphate-glucose and ribavirin as raw materials, and synthesizing the 3'-O-beta-glucosyl-ribavirin compound under the catalysis of a glycosyltransferase, the reaction condition is mild, the operation is simple, the yield is high, and the method is suitable for industrial production. The 3'-O-beta-glucosyl-ribavirin compound prepared by the application has obvious inhibitory effect on influenza virus and enterovirus, and the antiviral effect is higher than that of the present clinical drug ribavirin, and the 3'-O-beta-glucosyl-ribavirin compound can be used as an antiviral drug candidate.

The invention belongs to the technical field of animal medicine, and particularly relates to a tortoise respiratory tract infection non-irritant nebulization treatment medicine and a using method thereof.The medicine comprises a first round of nebulization medicine and a second round of nebulization medicine, and the first round of nebulization medicine comprises 10 ml of normal saline and 0.2 ml of aminophylline; and the second-round atomized medicine comprises 10ml of normal saline, 50mg of amikacin, 1mg of dexamethasone and 10mg of ribavirin, and is formed by mixing the normal saline, the amikacin, the dexamethasone and the ribavirin. The using method comprises the steps of early-stage preparation, medicine preparation and atomization operation. According to the tortoise respiratory tract infection non-irritant atomization treatment medicine and the using method thereof, staged synergistic treatment is achieved, and the progressive administration logic of spasmolysis and infection resistance is initiated for the first time; a non-irritant formula is adopted, and zero-damage treatment of the respiratory tracts of turtles is achieved for the first time; the atomization box is used for simulating the original environment of the Dabie mountain, the vicious circle of'stress-food refusal-immunity decline 'of the existing turtles is solved, the integration of'treatment and maintenance' is realized through environment simulation and time control, and the healing effect is improved.